HbA1c Performance in African Descent Populations in the United States With Normal Glucose Tolerance, Prediabetes, or Diabetes: A Scoping Review
SYSTEMATIC REVIEW — Volume 18 — March 11, 2021
Records of 3,238 studies were identified by searching databases. Of these, 157 duplicate records were removed. The remaining records were screened by title and abstract; 3,035 were excluded for the following reasons: type 1 diabetes, 98; age exclusively less than 19 years or greater than 64 years, 217; subject was animals or objects, 22; study conducted outside the United States, 422; generalized African descent populations as one group, 58; did not report HbA1c performance in African descent populations, 631; dietary studies, 30; other diseases, disorders, complications (including diabetes-related complications), illnesses investigated (eg, kidney), 933; treatment or interventional studies, 527; gestational diabetes, 13; and genetic studies, 84. The full text of the remaining 46 articles was assessed for eligibility; 34 were excluded for insufficient data (6), for being a narrative review (10), and a reason not previously detected in the title or abstract (18). This resulted in 12 studies being included in the qualitative synthesis.
Flow diagram of the study selection process for glycated hemoglobin A1c(HbA1c) testing performance in African descent populations in the United States, using PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). Studies were published January 1, 2000, to January 1, 2020.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.